Volery, FrançoisFrançoisVoleryBanz, YaraYaraBanz0000-0003-4474-3132Heini, AlexanderAlexanderHeiniKronig, Marie-NoëlleMarie-NoëlleKronigSiegrist, DanielDanielSiegristDaskalakis, MichaelMichaelDaskalakisBacher, UlrikeUlrikeBacherPabst, ThomasThomasPabst2024-11-082024-11-082024https://boris-portal.unibe.ch/handle/20.500.12422/188820Introduction The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging.Case Presentation We report the case of a patient developing acute erythroid leukemia with biallelic TP53 inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma. The patient presented with a healthy bone marrow prior to lymphoma treatments.Discussion Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.enAcute erythroid leukemiaAcute myeloid leukemiaBrexucabtagene autoleucelCAR-TMantle cell lymphomaarticle10.48620/761153947455010.1159/000541256